Vanda Pharmaceuticals Inc. (VNDA)

NASDAQ: VNDA · IEX Real-Time Price · USD
9.92
0.03 (0.30%)
May 20, 2022 4:00 PM EDT - Market closed
Market Cap560.38M
Revenue (ttm)266.21M
Net Income (ttm)18.07M
Shares Out56.49M
EPS (ttm)0.32
PE Ratio30.71
Forward PE30.30
Dividendn/a
Ex-Dividend Daten/a
Volume464,073
Open9.95
Previous Close9.89
Day's Range9.63 - 10.13
52-Week Range9.24 - 21.86
Beta0.59
AnalystsSell
Price Target10.20 (+2.8%)
Earnings DateMay 5, 2022

About VNDA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment...

IndustryBiotechnology
IPO DateApr 12, 2006
CEOMihael Polymeropoulos
Employees278
Stock ExchangeNASDAQ
Ticker SymbolVNDA
Full Company Profile

Financial Performance

In 2021, VNDA's revenue was $268.68 million, an increase of 8.27% compared to the previous year's $248.17 million. Earnings were $33.15 million, an increase of 42.06%.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for VNDA stock is "Sell." The 12-month stock price forecast is 10.2, which is an increase of 2.82% from the latest price.

Price Target
$10.2
(2.82% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Vanda Pharmaceuticals Announces Presentations at DDW 2022

WASHINGTON , May 19, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at Digestive Disease Week (DDW) 2022, to be held in San Diego, CA and online fro...

1 day ago - PRNewsWire

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -1,000% and 3.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Vanda Pharmaceuticals Reports First Quarter 2022 Financial Results

WASHINGTON , May 5, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2022. "We are excited w...

2 weeks ago - PRNewsWire

Vanda Pharmaceuticals Announces Participation in the BofA Securities 2022 Healthcare Conference

WASHINGTON, May 4, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the BofA Securities 2022 Healthcare Conference in Las Vegas...

2 weeks ago - PRNewsWire

Vanda Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 5, 2022

Conference Call and Webcast to Follow WASHINGTON, April 28, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2022 on T...

3 weeks ago - PRNewsWire

Earnings Preview: Vanda Pharmaceuticals (VNDA) Q1 Earnings Expected to Decline

Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

WASHINGTON, Feb. 23, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2021...

2 months ago - PRNewsWire

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

WASHINGTON, Feb. 17, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2021 on Wednesday, February 23, 2...

3 months ago - PRNewsWire

Why Are Vanda Pharma Shares Plunging Today?

Vanda Pharmaceuticals Inc  VNDA shares are plunging after the company announced Phase 3 trial data of tradipitant in treating the symptoms of gastroparesis.  Get the Inside Access Traders Are Using to P...

3 months ago - Benzinga

Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis

WASHINGTON, Feb. 4, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced results from its Phase III clinical study, VP-VLY-686-3303, evaluating the efficacy and safety ...

3 months ago - PRNewsWire

Vanda Pharmaceuticals Settles HETLIOZ® Patent Litigation with MSN

WASHINGTON, Jan. 14, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it has entered into a License Agreement (the License Agreement) with MSN Pharmaceuticals Inc.,...

4 months ago - PRNewsWire

Vanda Pharmaceuticals Announces Participation at November 2021 Investor Conferences

WASHINGTON, Nov. 10, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda management will participate at the following upcoming investor conferences in Novem...

6 months ago - PRNewsWire

Vanda Pharmaceuticals (VNDA) Misses Q3 Earnings and Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -30.00% and -4.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Vanda Pharmaceuticals: Q3 Earnings Insights

Vanda Pharmaceuticals (NASDAQ:VNDA) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

6 months ago - Benzinga

Vanda Pharmaceuticals Reports Third Quarter 2021 Financial Results

WASHINGTON, Nov. 3, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2021. "Vanda is app...

6 months ago - PRNewsWire

Vanda Pharmaceuticals Earnings Preview

Vanda Pharmaceuticals (NASDAQ:VNDA) is set to give its latest quarterly earnings report on Wednesday, 2021-11-03. Here's what investors need to know before the announcement.

6 months ago - Benzinga

Vanda Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 3, 2021

WASHINGTON, Oct. 27, 2021 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2021 on Wednesday, November 3, 2021, after the ...

6 months ago - PRNewsWire

Vanda Pharmaceuticals (VNDA) Earnings Expected to Grow: What to Know Ahead of Q3 Release

Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Vanda Pharmaceuticals Announces Participation at Evercore ISI's Catalyst Day

WASHINGTON, Oct. 14, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at Evercore ISI's Catalyst Day on Monday, October 18, 2021. Mihael H....

7 months ago - PRNewsWire

Vanda (VNDA) Upgraded to Buy: Here's Why

Vanda (VNDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

7 months ago - Zacks Investment Research

Vanda Pharmaceuticals Announces Participation at the Citi 16th Annual BioPharma Virtual Conference

WASHINGTON, Sept. 7, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda's management will participate at the Citi 16th Annual BioPharma Virtual Conference ...

8 months ago - PRNewsWire

Vanda (VNDA) Loses 21.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Vanda (VNDA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earni...

9 months ago - Zacks Investment Research

Vanda Pharmaceuticals Closes Enrollment In The ODYSSEY Study Comparing Tradipitant And Placebo In Hospitalized COVID-...

WASHINGTON, Aug. 3, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that enrollment has closed in the ODYSSEY study comparing tradipitant and placebo in hospitaliz...

9 months ago - PRNewsWire

Vanda (VNDA) Upgraded to Buy: What Does It Mean for the Stock?

Vanda (VNDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

9 months ago - Zacks Investment Research

Vanda Pharmaceuticals (VNDA) Matches Q2 Earnings Estimates

Vanda (VNDA) delivered earnings and revenue surprises of 0.00% and -4.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research